{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T04:47:03Z","timestamp":1775191623138,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematopathol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Multiple myeloma is a clonal plasma cell malignancy often characterized by complex cytogenetic abnormalities that influence prognosis and treatment strategies. This report describes a 63-year-old male with kappa light chain multiple myeloma and a rare finding of double translocation involving t(11;14) and t(14;16), detected by FISH analysis. This case emphasizes the clinical implications of such genetic abnormalities and their impact on disease progression and therapeutic decisions.<\/jats:p>","DOI":"10.1007\/s12308-025-00626-w","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T10:07:20Z","timestamp":1743329240000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A rare case of multiple myeloma with double translocations: t(11;14) and t(14;16)"],"prefix":"10.1007","volume":"18","author":[{"given":"Mina","family":"Meseha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishw","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirolos","family":"Sekla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Coffey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"issue":"33","key":"626_CR1","first-page":"159","volume":"1","author":"BA Walker","year":"2018","unstructured":"Walker BA, Mavrommatis K, Wardell CP et al (2018) (2018) A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia 1(33):159\u2013170","journal-title":"Leukemia"},{"key":"626_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1053\/j.seminoncol.2022.01.006","volume":"49","author":"M Chojnacka","year":"2022","unstructured":"Chojnacka M, Diamond B, Landgren O, Maura F (2022) Defining genomic events involved in the evolutionary trajectories of myeloma and its precursor conditions. Semin Oncol 49:11\u201318","journal-title":"Semin Oncol"},{"key":"626_CR3","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538\u2013e548","journal-title":"Lancet Oncol"},{"key":"626_CR4","doi-asserted-by":"crossref","unstructured":"Editor C, Tefferi A, Vincent Rajkumar S. (2016) Multiple myeloma: 2016 update on diagnosis risk-stratification and management. Am J Hematol. 91 719\u2013734","DOI":"10.1002\/ajh.24402"},{"key":"626_CR5","first-page":"2950","volume":"12","author":"S Bal","year":"2022","unstructured":"Bal S, Kumar SK, Fonseca R, Gay F, Hungria VT, Dogan A, Costa LJ (2022) Multiple myeloma with t(11;14): unique biology and evolving landscape. Am J Cancer Res 12:2950","journal-title":"Am J Cancer Res"},{"issue":"1","key":"626_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-023-00807-9","volume":"13","author":"B Puertas","year":"2023","unstructured":"Puertas B, Gonz\u00e1lez-Calle V, Sobejano-Fuertes E, Escalante F, Rey-Bua B, Padilla I, Garc\u00eda-Sanz R, Puig N, Guti\u00e9rrez NC, Mateos MV (2023) Multiple myeloma with t(11;14) impact of novel agents on outcome. Blood Cancer J 13(1):1\u20138","journal-title":"Blood Cancer J"},{"key":"626_CR7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1182\/blood-2021-145757","volume":"138","author":"S Kumar","year":"2021","unstructured":"Kumar S, Harrison SJ, Cavo M et al (2021) Final overall survival results from BELLINI, a phase 3 study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed\/refractory multiple myeloma. Blood 138:84","journal-title":"Blood"},{"key":"626_CR8","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S1470-2045(20)30587-8","volume":"21","author":"I Ghobrial","year":"2020","unstructured":"Ghobrial I (2020) BELLINI: a renaissance for an era of precision therapy in multiple myeloma. Lancet Oncol 21:1547\u20131549","journal-title":"Lancet Oncol"},{"issue":"1","key":"626_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-023-00933-4","volume":"13","author":"A Schavgoulidze","year":"2023","unstructured":"Schavgoulidze A, Perrot A, Cazaubiel T et al (2023) Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions. Blood Cancer J 13(1):1\u20133","journal-title":"Blood Cancer J"},{"key":"626_CR10","doi-asserted-by":"publisher","first-page":"101168","DOI":"10.1016\/j.blre.2024.101168","volume":"64","author":"SE Clarke","year":"2024","unstructured":"Clarke SE, Fuller KA, Erber WN (2024) Chromosomal defects in multiple myeloma. Blood Rev 64:101168","journal-title":"Blood Rev"},{"key":"626_CR11","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1158\/1078-0432.CCR-10-1843","volume":"17","author":"NC Munshi","year":"2011","unstructured":"Munshi NC, Avet-Loiseau H (2011) Genomics in multiple myeloma. Clin Cancer Res 17:1234\u20131242","journal-title":"Clin Cancer Res"},{"issue":"7","key":"626_CR12","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","volume":"15","author":"SK Kumar","year":"2018","unstructured":"Kumar SK, Rajkumar SV (2018) The multiple myelomas \u2014 current concepts in cytogenetic classification and therapy. Nat Rev Clin Oncol 15(7):409\u2013421","journal-title":"Nat Rev Clin Oncol"},{"key":"626_CR13","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s10038-023-01136-2","volume":"68","author":"T Tsukamoto","year":"2023","unstructured":"Tsukamoto T, Kinoshita M, Yamada K et al (2023) Imaging flow cytometry-based multiplex FISH for three IGH translocations in multiple myeloma. J Hum Genet 68:507\u2013514","journal-title":"J Hum Genet"},{"key":"626_CR14","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s00277-012-1668-y","volume":"92","author":"M Ji","year":"2013","unstructured":"Ji M, Jang S, Lee JH, Seo EJ (2013) Double-hit myeloma with IGH\/MYC and IGH\/CCND1 translocations. Ann Hematol 92:1129\u20131131","journal-title":"Ann Hematol"},{"key":"626_CR15","first-page":"8811114","volume":"2020","author":"M Yasumi","year":"2020","unstructured":"Yasumi M, Endo T, Sata H, Karasuno T (2020) Double-hit primary plasma cell leukemia with IGH\/MYC and IGH\/CCND1 translocations. Case Rep Hematol 2020:8811114","journal-title":"Case Rep Hematol"},{"key":"626_CR16","doi-asserted-by":"publisher","first-page":"e710","DOI":"10.1016\/j.clml.2021.05.001","volume":"21","author":"A Ravindran","year":"2021","unstructured":"Ravindran A, Greipp PT, Wongchaowart N, Smadbeck JB, Peterson JF, Ketterling RP, Kumar SK, Baughn LB (2021) Dual primary IGH translocations in multiple myeloma: a novel finding. Clin Lymphoma Myeloma Leuk 21:e710\u2013e713","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"626_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms3997","volume":"5","author":"N Bolli","year":"2014","unstructured":"Bolli N, Avet-Loiseau H, Wedge DC et al (2014) Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun 5:1\u201313","journal-title":"Nat Commun"},{"key":"626_CR18","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1182\/blood-2012-01-405985","volume":"120","author":"JJ Keats","year":"2012","unstructured":"Keats JJ, Chesi M, Egan JB et al (2012) Clonal competition with alternating dominance in multiple myeloma. Blood 120:1067\u20131076","journal-title":"Blood"},{"issue":"5","key":"626_CR19","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrc3257","volume":"12","author":"GJ Morgan","year":"2012","unstructured":"Morgan GJ, Walker BA, Davies FE (2012) The genetic architecture of multiple myeloma. Nat Rev Cancer 12(5):335\u2013348","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"626_CR20","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1038\/s41375-019-0689-0","volume":"34","author":"F Maura","year":"2020","unstructured":"Maura F, Rustad EH, Yellapantula V et al (2020) (2019) Role of AID in the temporal pattern of acquisition of driver mutations in multiple myeloma. Leukemia 34(5):1476\u20131480","journal-title":"Leukemia"},{"key":"626_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms7997","volume":"6","author":"BA Walker","year":"2015","unstructured":"Walker BA, Wardell CP, Murison A et al (2015) APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat Commun 6:1\u201311","journal-title":"Nat Commun"},{"key":"626_CR22","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.semcdb.2021.04.014","volume":"123","author":"F Maura","year":"2022","unstructured":"Maura F, Boyle EM, Rustad EH et al (2022) Chromothripsis as a pathogenic driver of multiple myeloma. Semin Cell Dev Biol 123:115\u2013123","journal-title":"Semin Cell Dev Biol"},{"key":"626_CR23","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1038\/s41375-018-0223-9","volume":"32","author":"C Touzeau","year":"2018","unstructured":"Touzeau C, Maciag P, Amiot M, Moreau P (2018) Targeting Bcl-2 for the treatment of multiple myeloma. Leukemia 32:1899\u20131907","journal-title":"Leukemia"},{"key":"626_CR24","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1182\/blood.2020007899","volume":"137","author":"VA Gupta","year":"2021","unstructured":"Gupta VA, Barwick BG, Matulis SM et al (2021) Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. Blood 137:3604\u20133615","journal-title":"Blood"},{"key":"626_CR25","doi-asserted-by":"publisher","first-page":"934008","DOI":"10.3389\/fonc.2022.934008","volume":"12","author":"MD Diamantidis","year":"2022","unstructured":"Diamantidis MD, Papadaki S, Hatjiharissi E (2022) Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation. Front Oncol 12:934008","journal-title":"Front Oncol"},{"key":"626_CR26","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood.2023020276","volume":"143","author":"N Leblay","year":"2024","unstructured":"Leblay N, Ahn S, Tilmont R et al (2024) Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency. Blood 143:42\u201356","journal-title":"Blood"},{"key":"626_CR27","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.3390\/cancers13122974","volume":"13","author":"HT Salah","year":"2021","unstructured":"Salah HT, Dinardo CD, Konopleva M, Khoury JD (2021) Potential biomarkers for treatment response to the BCL-2 inhibitor venetoclax: state of the art and future directions. Cancers 13:2974","journal-title":"Cancers"}],"container-title":["Journal of Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12308-025-00626-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12308-025-00626-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12308-025-00626-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T10:07:23Z","timestamp":1743329243000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12308-025-00626-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["626"],"URL":"https:\/\/doi.org\/10.1007\/s12308-025-00626-w","relation":{},"ISSN":["1868-9256","1865-5785"],"issn-type":[{"value":"1868-9256","type":"print"},{"value":"1865-5785","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"assertion":[{"value":"6 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11"}}